Sagimet Biosciences Inc.
SGMT
Rank in Stocks
#13966
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The companyโs lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Share Price
$10.83
Last synced: 2026-11-09
Market Cap
$352.86M
Change (1 day)
9.95%
Change (1 year)
27.41%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Sagimet Biosciences Inc. (SGMT)
Category
Healthcare
Operating Margin for Sagimet Biosciences Inc. (SGMT)
Operating Margin as of November 2026 TTM: 0.00%
According to Sagimet Biosciences Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Sagimet Biosciences Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -1,537.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Sagimet Biosciences Inc.'s operating margin
What was Sagimet Biosciences Inc.'s operating margin in 2025?
In 2025, Sagimet Biosciences Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Sagimet Biosciences Inc.'s operating margin changed since 2020?
From 2020 to 2025, Sagimet Biosciences Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2023 (-1,537.00%).
How does Sagimet Biosciences Inc.'s operating margin compare with similar companies?
Sagimet Biosciences Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.